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There is a need to better understand inhalational anthrax in relevant animal models.
This understanding could aid risk assessment, help define therapeutic windows, and
provide a better understanding of disease. The aim here was to characterize and quantify
bacterial deposition and dissemination in rabbits following exposure to single high aerosol
dose (>100 LD50) of Bacillus anthracis (Ames) spores immediately following exposure
through 36 h. The primary goal of collecting the data was to support investigators in
developing computational models of inhalational anthrax disease. Rabbits were vaccinated
prior to exposure with the human vaccine (Anthrax Vaccine Adsorbed, AVA) or were
sham-vaccinated, and were then exposed in pairs (one sham and one AVA) so disease
kinetics could be characterized in equally-dosed hosts where one group is fully protected
and is able to clear the infection (AVA-vaccinated), while the other is susceptible to disease,
in which case the bacteria are able to escape containment and replicate uncontrolled
(sham-vaccinated rabbits). Between 4–5% of the presented aerosol dose was retained
in the lung of sham- and AVA-vaccinated rabbits as measured by dilution plate analysis
of homogenized lung tissue or bronchoalveolar lavage (BAL) fluid. After 6 and 36 h,
>80% and >96%, respectively, of the deposited spores were no longer detected in
BAL, with no detectable difference between sham- or AVA-vaccinated rabbits. Thereafter,
differences between the two groups became noticeable. In sham-vaccinated rabbits the
bacteria were detected in the tracheobronchial lymph nodes (TBLN) 12 h post-exposure
and in the circulation at 24 h, a time point which was also associated with dramatic
increases in vegetative CFU in the lung tissue of some animals. In all sham-vaccinated
rabbits, bacteria increased in both TBLN and blood through 36 h at which point in time
some rabbits succumbed to disease. In contrast, AVA-vaccinated rabbits showed small
numbers of CFU in TBLN between 24 and 36 h post-exposure with small numbers of
bacteria in the circulation only at 24 h post-exposure. These results characterize and
quantify disease progression in naïve rabbits following aerosol administration of Ames
spores which may be useful in a number of different research applications, including
developing quantitative models of infection for use in human inhalational anthrax risk
assessment.
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INTRODUCTION
Anthrax is an infectious disease caused by Bacillus anthracis, a
gram-positive, non-motile, spore-forming bacterium (Brachman
et al., 1960; Dixon et al., 1999; Grinberg et al., 2001; Mock
and Fouet, 2001; Frazier et al., 2006). In humans, exposure
results from contact, ingestion or inhalation of spores lead-
ing to three distinct clinical diseases: cutaneous, gastrointestinal,
and inhalational, respectively. Inhalational anthrax is the most
lethal form of the disease and exposure to respirable spores
has been a longstanding concern in biodefense (Frazier et al.,
2006). Indeed, the ability of B. anthracis to induce morbidity and
mortality as a bioweapon was demonstrated in the fall of 2001
when spore-laced letters were sent through the US mail system
causing five inhalational anthrax fatalities (Dewan et al., 2002;
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Jernigan et al., 2002; Holtz et al., 2003). Today, B. anthracis may
represent the single greatest biological warfare threat (Cleret et al.,
2007).
Two important components in successfully protecting people
are to better define the risk of disease in man and to develop
effective therapeutics (Inglesby et al., 1999, 2002; Canter, 2005;
Yee et al., 2010). However, because naturally occurring inhala-
tional anthrax in man is exceptionally rare and therefore the data
describing human inhalational anthrax disease is limited, work
toward meeting these two goals must rely heavily on informa-
tion obtained from relevant inhalational anthrax animal models
(Hambleton et al., 1994; Watson and Keir, 1994; Frazier et al.,
2006; see also FDA two-animal rule- 21 C.F.R. §314.610, drugs;
§601.91, biologics). Here, the rabbit and non-human primate are
often cited as the most appropriate animal models for use in
generating data relevant to human inhalational anthrax, at least
from a perspective of testing therapeutics or comparing patho-
logical lesions during the end stage of disease. Thus, research that
advances our quantitative understanding of inhalational anthrax
in the rabbit will contribute to a better understanding of dis-
ease and help decision makers prepare in defense against future
attacks.
A leading hypothesis in disease initiation and spread suggests
inhaled spores are deposited in the conducting airwayswhere they
are quickly phagocytosed by alveolar macrophages (Ross, 1957;
Dixon et al., 1999; Guidi-Rontani et al., 1999; Guidi-Rontani,
2002). The spores are then transported to the draining lymph
nodes due to the migratory capacity of the alveolar macrophage.
It is thought that spores germinate inside the macrophages either
en route to the lymph node or immediately after reaching the
lymph node (Dixon et al., 1999; Guidi-Rontani et al., 1999;
Guidi-Rontani, 2002; Ireland and Hanna, 2002). Germination
is associated with lethal toxin and edema toxin production that
enable the bacteria to escape from themacrophage and enter a sig-
nificant growth phase extracellular to host immune cells (Loving
et al., 2009). Bacteria then spread via the efferent lymph system,
and are eventually released into the blood at the thoracic duct.
Bacterial replication in the circulation quickly follows and at the
time of death bacterial levels can reach 1010 bacteria/ml blood.
Although much data has been collected in support of this hypoth-
esis, other work suggests alternative pathogenesis pathways may
be involved. For example, deposited spores may interact with den-
dritic cells or epithelial cells during the early stages of disease
(Shetron-Rama et al., 2010; Weiner and Glomski, 2012).
Although the research cited above provides insight into pos-
sible mechanisms associated with inhalational anthrax disease
initiation and dissemination, one potential limitation in this body
of work is that much of the research has been conducted in mice
using attenuated strains of B. anthracis. Comparable detailed and
mechanistic studies using larger animals like rabbits, where fully
virulent spores are delivered via aerosols, are far more limited
although some recent work describing natural history in the rab-
bit following aerosol exposure to Ames spores has been published
(Lawrence et al., 2009; Yee et al., 2010). Clearly, the risk to labo-
ratory personnel when aerosolizing fully virulent strains and the
cost associated with larger animal BSL-3 aerosol studies are pri-
mary drivers in limiting the amount of work conducted to date
in the rabbit. It should also be noted that additional advantages
of working with mouse models compared to rabbits are that there
is a far better understanding of the mouse immune system and
there are considerably more reagents (such as antibodies) avail-
able for mouse studies than those for rabbits. However, if rabbit
models of inhalational anthrax are considered appropriate for
development and testing of therapeutics and the study of the end
stages of inhalational anthrax disease (21 C.F.R. §314.610, drugs;
§601.91, biologics), then additional work should be conducted
that examines disease initiation and progression in this host.
The current work examined disease initiation and kinetics
in the New Zealand white (NZW) rabbit model of inhalational
anthrax following exposure to aerosols of fully virulent Ames
spores. The mean time to death of rabbits has been reported at
2.4 days and the LD50 is estimated at 1.05 × 105 Ames spores
(Zaucha et al., 1998; Fellows et al., 2001; Pitt et al., 2001; Phipps
et al., 2004). Our experimental design consisted of exposing naïve
animals to high (lethal, >100 LD50) doses of Ames aerosols and
then quantifying the number of bacteria in different tissues as
disease progressed. Bacteria were quantified from 0 to 36 h post-
exposure in the conducting airways, lung tissue, lymph nodes
and circulation. A main experimental control for the infection
in naïve rabbits were rabbits challenged with the same aerosol
dose but were also vaccinated with the human anthrax vaccine
(AnthraxVaccine Adsorbed, AVA). AVA is fully protective inNZW
rabbits exposed to a lethal dose of Ames spores (Fellows et al.,
2001; Pitt et al., 2001). By pairing non-vaccinated with AVA-
vaccinated rabbits during the exposures, host-pathogen responses
that demonstrate vastly different outcomes in response to the
same inhaled dose could be studied. Since the vaccine is fully pro-
tective in rabbits, vaccinated rabbits were able to completely clear
all deposited spores, whereas in the non-vaccinated rabbit spores
escaped from the immune system and entered an outgrowth
phase leading to bacteremia and death.
MATERIALS ANDMETHODS
B. anthracis AMES STRAIN
Ames strain bacteria (pXO1+ and pXO2+) were obtained fromC.
Rick Lyons of the University of New Mexico. Spores were grown
in trypticase soy broth supplemented with 100mg/L manganese
sulfate in a shaker incubator (225 revolutions per minute) at 37◦C
for approximately 96 h. Spores were harvested by centrifugation,
then re-suspended in sterile phosphate buffered saline (PBS), and
stored at 4–6◦C. Spore were heat shocked at 65◦C ± 2◦C imme-
diately prior to use and the titer was determined before each
exposure using standard dilution plating techniques (Turnbull
et al., 2007).
ANIMALS
Certified Pasteurella-free male NZW rabbits were obtained from
Covance Research Products (Denver, CO) and weighed between
2–4 kg at the time of aerosol exposures. Rabbits were fed Teklad
Certified Global High Fiber Rabbit Diet (Harlan Teklad,Madison,
WI), 150 g, once daily and had unrestricted access to municipal
water ad libitum. Controlled environmental conditions included
temperature (18–29◦C), relative humidity (30–70%) and light
(12 h on and 12 h off).
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VACCINATION
Rabbits were vaccinated with an intramuscular injection of 0.5ml
AVA (Biothrax™, Bioport Corporation, Lansing, MI; lot numbers
FAV158, FAV114, FAV102 that was obtained through MILVAX)
or were sham-vaccinated with an equal volume of PBS/2%
Alhydrogel (Sham). Alhydrogel was obtained from Brenntag
Biosector (Frederikssund, Denmark). Injections occurred at week
0 (Day 0) and again at week 4 (Day 28) and the animals were
challenged with aerosols of Ames spores at week 10 (day 70)
(Fellows et al., 2001; Pitt et al., 2001). Most of the data pre-
sented in the current work were collected within 36 h following
aerosol exposure. However, a portion of the rabbits were not
sacrificed at the predetermined time point and were held for
two weeks where AVA-vaccination proved 100% protective in all
rabbits.
BIOAEROSOL CHALLENGEWITH Bacillus anthracis AMES STRAIN
Exposures occurred at the Lovelace Respiratory Research
Institute, Albuquerque, MN. Rabbits were weighed and randomly
assigned to exposure groups and subgroups using a comput-
erized data acquisition system (Path-Tox 4.2.2; Xybion, Cedar
Knolls, NJ). Body weights of individual animals did not exceed
± 20% of the groups mean. All data presented in the cur-
rent work were generated from two sets of exposures. The first
occurred during the months of September–December, 2006 and
the second during the months of October, 2007 to January, 2008.
Rabbits were placed into muzzle-only exposure boxes for 10, 30,
and 45min on three consecutive days prior to bioaerosol chal-
lenge for conditioning. Unless otherwise noted, all exposures
lasted 16min which was the exposure time required to reach the
targeted presented dose given experimental setup. Rabbits sacri-
ficed at 6, 12, 24, or 36 h post-exposure were exposed in pairs-
one AVA-vaccinated paired with one sham-vaccinated rabbit. All
rabbits were sacrificed using Euthasol or pentobarbital sodium.
Rabbits sacrificed immediately following the end of the expo-
sure were exposed one at a time and were exposed by alternating
between one sham-vaccinated and one AVA-vaccinated animal.
This allowed examination of each animal as soon as possible
following the end of the exposure. The mean time required to
decontaminate and remove a given animal from the exposure
chamber to the beginning of euthanasia was 9.4 ± 1.2min and
the mean time from start of euthanasia to necropsy was 10.2
± 0.53min. Thus, the time from first inhaling a spore to the
time of necropsy ranged from 30 to 45min and are identified
as 1 h in the Tables and Figures, or “without delay” or “imme-
diately” in the text. Spores were aerosolized in PBS plus 0.01%
Triton-X using a 3-jet collison nebulizer. The mean mass aero-
dynamic diameter of the spores was 1.0 ± 0.3µm as measured
using a TSI Aerosol Particle Sizer (TSI, Inc., Shoreview, MN).
Aerosols were collected in all glass impingers (AGI) containing
PBS + 0.01% Triton-X + antifoam. Aerosol dose was mea-
sured using a Buxco plethysmography system (Buxco Electronics,
Wilmington, NC) on each animal. Animals were observed daily
andmoribund animals were euthanized immediately. In conduct-
ing this research, investigators adhered to the Guide for the Care
and Use of Laboratory Animals [NIH publication 86-23, revised
1985].
BACTERIAL QUANTIFICATION IN HOMOGENIZED LUNG TISSUE
The bacterial load in the lung at a given time point was deter-
mined by dilution plate analysis of homogenized lung tissue.
Here, immediately after sacrifice portions of the (non-lavaged)
right middle lobe were excised, weighed (0.440 ± 0.001 g, average
weight), and homogenized in 50ml sterile PBS with 1% pep-
tone at 4◦C using a tissue homogenizer (Precision disposable
tissue grinder system, VWR Scientific). Thereafter, an aliquot
of the homogenate was plated on tryptic soy agar (TSA) plates
(Hardy Diagnostics, Santa Maria, CA). The density of the lung
homogenate (0.999 g/ml) was used to convert colony forming
unit/ml (CFU/ml) to CFU/gram of lung tissue. In independent
studies, the total average weight of the rabbit lung was determined
from five non-treated, age- and weight-matched control animals.
The mean mass was 17.00 ± 2.4 g and was used to convert all
CFU/gram tissue data to CFU/whole lung. Total CFU and spores
were determined by plating a non-heated and heated aliquot of
the homogenate, respectively. Unless otherwise noted, the differ-
ence between total CFU and spores represented the number of
heat-sensitive vegetative bacteria.
QUANTIFICATION OF BACTERIA AND ALVEOLAR MACROPHAGES
IN BRONCHOALVEOLAR LAVAGE (BAL) FLUID
The bacterial load in the conducting airways at a given time
point post-exposure was a main data set we aimed to collect in
this work and CFU were determined by dilution plate analysis
of bronchoalveolar lavage (BAL) fluid. In addition to CFU in
BAL, we also determined the number of macrophages in each
BAL sample. The primary goal in collecting macrophage data
was to help assess lavage efficiency in recovering deposited spores
from all airways (discussed below), but these data are also use-
ful in gaining better insight into the host immune response, and
are also directly applicable to computational models of inhala-
tional anthrax where alveolar macrophage numbers and function
in the conducting airways pre- and post-exposure are key vari-
ables (Gutting et al., 2008; Day et al., 2011). Here, immediately
after sacrifice the right lobes were clamped using a hemostat and
the left three lobes were inflated two separate times with sterile
saline (4◦C) using a syringe. The two individual BAL samples
were then pooled into a single BAL sample per animal. Each BAL
sample was weighed and a density of 1.001 g/ml was used to cal-
culate a total BAL volume. Prior to dilution plate analysis with
or without heat kill (65◦C for 30min), BAL samples were soni-
cated in an attempt to liberate any phagocytosed bacteria because
there was concern that if a macrophage had engulfed multiple
spores then this would be reflected as a single CFU on the TSA
plate. Thus, the goal was to effectively destroy all macrophages
in the BAL sample without affecting the viability of spores or
vegetative bacteria when plated on TSA plates. A water bath
sonicator was used (Misonix Sonicator 3000 Ultrasonic Liquid
Processor, Misonix, Inc, Farmingdale, NY) set at 25% amplitude
for 3min. Preliminary studies using either freshly isolated rabbit
alveolar macrophages from non-treated animals, purified Ames
spores, or freshly isolated Ames bacteria grown to log-phase, sug-
gested that this treatment completely killed and disintegrated
all macrophages while there was no observable effect on spore
numbers and minimal effects on vegetative cells numbers.
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It was recognized that lavaging the airway two times was
insufficient to wash out all the deposited spores. Therefore, a cor-
rection factor was needed to estimate the fraction of bacteria left
in the airways following two lavages. This correction factor was
determined by calculating the number of macrophages obtained
from repeated lavages in control animals and then assuming
the spores and macrophages can be lavaged with the same effi-
ciency. Here, the left lobes from a group of five non-treated,
age- and weight-matched rabbits were lavaged between two and
eight times. The total number of alveolar macrophages recovered
following two lavages was 8.02 ± 3.02 (×106). The number of
recovered macrophages increased with more lavages and peaked
at 21.22 ± 5.98 (×106) following eight lavages. Thus, there was a
2.645 fold difference in recovered macrophages following two or
eight lavages and therefore the BAL bacterial data was adjusted by
2.645.
Total bacterial numbers in the lower airways were calculated
using the dilution series plate data, BAL density, the weight of the
pooled BAL sample, a 2.65 correction factor, and finally a factor
of two to reflect that only half the lung was lavaged.
Alveolar macrophages were determined using a hemacytome-
ter. Trypan dye exclusion was used to determine viability. All cells
with an approximate diameter of 15µm in the BAL samples were
counted as an alveolar macrophage.
BACTERIAL QUANTIFICATION IN LYMPH NODES AND BLOOD
At the respective time point, tracheobronchial lymph nodes
(TBLN) were removed and homogenized as described above for
lung tissue. Due to their small size, the entire TBLN was homog-
enized in 5ml sterile PBS with 1% peptone at 4◦C using a tissue
homogenizer (Precision disposable tissue grinder system, VWR
Scientific). CFU/lymph node was determined using homogenate
weight, density, and plate counts. For analysis of blood, an aliquot
of whole blood was collected using EDTA tubes and plated. A con-
version factor of 56ml blood/kg body weight was used to convert
CFU/ml blood to total CFU counts in the circulation.
STATISTICAL ANALYSIS
Unless otherwise stated, all data presented here are mean standard
error of the mean (SEM). Student’s t test was used for pair-wise
comparisons.
RESULTS
PRESENTED DOSE OF AMES SPORES
AVA- or sham-vaccinated NZW rabbits were exposed to heat-
shocked Ames spores (65◦C ± 2◦, 30min). As shown in Table 1,
the mean presented dose of viable Ames spores was 44.28 ± 5.7
(×106) CFU, which corresponded to an average dose of 422 LD50.
These data were collected by dilution plating aliquots (without
heat treatment) from the AGIs. In addition, AGI aliquots were
also treated at 65◦C ± 2◦ for 30min prior to plating. Here, the
number of heat-resistant spores dropped approximately 30% to
28.51 ± 3.3 (×106) CFU (Table 1). Because the spores were heat-
shocked prior to aerosolization, these data suggested approxi-
mately 30% of the aerosolized spores remained viable when plated
on TSA plates, but were damaged sufficiently from the shear-
ing forces placed on them during the aerosolization process that
Table 1 | Presented dose of Ames spores.
Presented dose
(×106) LD50
Total spores 44.28 ± 5.7 422 ± 54
Heat resistant spores 28.51 ± 3.3 271 ± 32
Heat sensitive spores 15.77 ± 3.5 150 ± 33
% Inhaled heat resistant spores (×100) 69.30 ± 2.7%
% Inhaled heat sensitive spores (×100) 30.70 ± 2.7%
All values are mean ± SEM (n = 60) and are data pooled from six separate
exposure days where 10 rabbits were exposed each day.
they lost their heat-resistance. Thus, the average presented dose
was 44.28 ± 5.7 (×106) CFU, of which approximately 70% of
the spores were healthy and approximately 30% were damaged
(Table 1). It is unclear how damaged heat-sensitive spores behave
following deposition in relation to healthy heat-resistant spores,
but one conclusion that can be reached using this data is that
the detection of heat-sensitive CFU using standard dilution plate
analysis in the airways (from BAL) or the lung tissue homogenate
does not necessarily reflect in situ germination of newly deposited
spores, particularly in samples collected immediately following
exposure. Additional challenges in identifying germination in
ex vivo tissue samples are discussed inmore detail in the following
sections (see below).
LUNG DOSE (DEPOSITED DOSE) DETERMINED USING LUNG
HOMOGENATES
The lung tissue dose (deposited dose) was determined by enumer-
ation of bacteria in homogenized lung tissue that was obtained
immediately following exposure. As shown in Table 2, 10 rab-
bits were exposed to an average of 19.58 ± 2.5 (×106) total
spores. The total number of viable bacteria recovered from
homogenized lung tissue was 0.93 ± 0.21 (×106), which repre-
sented 4.63 ± 1.1% of the presented dose. In an independent
study that used 12 rabbits, 4.03 ± 1.3% of the presented dose
was recovered in homogenized lung tissue, which was not sig-
nificantly different from the first study. Because approximately
30% of the inhaled spores were heat sensitive, it was not pos-
sible to assess spore germination in these samples using loss of
heat resistance as the indicator of germination. Therefore, the
data presented in Table 2 are total CFU recovered from lung
homogenate. It is also worth noting that at no time point exam-
ined in the current work (0–36 h post-exposure) do we use loss
of heat resistance as a measure of spore germination in lung tis-
sue homogenates for this very reason. In addition, previous work
by other investigators have also noted the challenges in detecting
germination in homogenized tissue samples due to experimen-
tal artifacts that can skew results. These include, in part, loss of
heat resistance resulting from the mechanical stresses placed on
spores during homogenization, increased pressure, exposure to
germinants from blood contaminants and/or the actual homog-
enization buffer introduced during tissue homogenization (the
buffer used in the current studies contained peptone, a potential
germinant), dose-effects where spore clumping or concentration
Frontiers in Cellular and Infection Microbiology www.frontiersin.org June 2012 | Volume 2 | Article 87 | 4
Gutting et al. Inhalational anthrax in the rabbit
Table 2 | Lung dose (deposited dose) determined by analysis of
homogenized lung tissue.
(×106)a % Presented dose
Presented doseb 19.58 ± 2.5 −
Total bacteria in homogenized
Lung tissue
0.93 ± 0.2 4.63 ± 1.1%c
aValues are mean ± SEM (n = 10).
bTotal viable Ames spores inhaled during the exposure.
c In an independent study, 12 rabbits inhaled 5.05 ± 0.5 (×106) Ames spores,
where 4.03 ± 1.3% were recovered in homogenized lung tissue immediately
following exposure.
at certain areas of the airways can occur at high doses, and the
method of euthanasia (Drysdale et al., 2005; Cote et al., 2006;
Heninger et al., 2006; Glomski et al., 2008). Despite these poten-
tially confounding issues in the germination state of bacteria in
lung homogenates, there is no indication in the literature, to
our knowledge, that bacteria can actually replicate during tis-
sue processing (lungs were homogenized in ice cold homogenate
immediately following necropsy). In summary, based on homog-
enizing lung tissue immediately following exposure, the total
number of viable CFU recovered from the lung from two inde-
pendent studies represented 4.03 ± 1.3% and 4.63 ± 1.1% of the
presented dose.
LUNG DOSE (DEPOSITED DOSE) DETERMINED FROM BAL
The deposited dose was also determined by analysis of BAL fluid
obtained immediately following exposure. These data are another
method of determining deposition which can be compared to
the deposition data obtained from lung tissue homogenates (see
above) and also serve as the starting point for analyzing how fast
bacteria are cleared from the airways over time following expo-
sure (see below). As discussed above, no attempt was made to
distinguish between dormant spores and germinated/germinating
spores and the data are reported as total CFU in BAL. As shown
in Table 3, 10 rabbits were exposed to an average of 19.58 ± 2.5
(×106) total spores. Immediately following exposure the BAL was
collected (two washes), sonicated, and plated on TSA plates. As
shown, the total number of bacteria in the BAL was 0.25 ± 0.07
(×106), which represented 1.16 ± 0.03% of the presented dose.
When adjusted by a factor of 2.65 (see Materials and Methods),
these data suggested 3.07 ± 0.9% of the presented dose was
recovered from the conducting airways immediately following
exposure. Although this value is lower than that determined by
homogenizing lung tissue (i.e., 4.63 ± 1.1% from Table 2), it was
not significantly different from it (p = 0.285 using a two tailed
Student’s t test). In an independent study using 12 rabbits, 1.33 ±
0.2% (mean± SEM) of the presented dose was recovered from the
airways. The most likely reason for the consistently smaller CFU
in BAL compared to lung homogenate is the inability to wash
out all deposited spores regardless of the number of lavages, but
another possible explanation is that some deposited spores may
have already crossed the epithelial lining en route to the draining
lymph nodes (see below) and are therefore not accessible using
lavage.
Table 3 | Lung dose (deposited dose) determined by analysis of BAL
fluid.
(×106)a % Presented dose
Presented doseb 19.58 ± 2.5 −
Total bacteria in sonicated
BAL fluid (2 washes)c
0.25 ± 0.07 1.16 ± 0.3%
Total bacteria in sonicated
BAL fluid (adjusted)d
− 3.07 ± 0.9%e
aValues are mean ± SEM (n = 10).
bTotal viable Ames spores inhaled during the exposure.
cTotal recovered bacteria in BAL fluid obtained following 2 lavages.
dTotal recovered bacteria in BAL fluid when adjusted by a factor of 2.65
(see Materials and Methods).
eIn an independent study using 12 rabbits, 1.33 ± 0.2% [adjusted] of the
presented dose was recovered in BAL fluid.
FATE OF DEPOSITED AMES SPORES AND KINETICS OF INFECTION
The next objective was to determine the fate of the deposited
spores in AVA-vaccinated and sham-vaccinated rabbits, and
attempt to quantify the infection as it spread from the conducting
airways to the circulation. Here, rabbits were sacrificed 6, 12, 24,
and 36 h following exposure (by 36 h, two sham-vaccinated rab-
bits had succumbed to infection- see Table 4). At the respective
time point, tissues were collected and the bacterial load deter-
mined. There are several points are worth noting in the analysis
that follows.
First, the number of bacteria present in the tissue at any given
time point following exposure is a function of the number of
deposited spores (i.e., a higher presented dose equals a higher
deposited dose which, in turn, equals a higher initial tissue dose).
For example, if 105 total bacteria were detected in the lung tis-
sue of a particular rabbit six h post-exposure, it is not possible
to conclude if the total number of bacteria were increasing (sug-
gesting an active infection) or decreasing without knowing how
many were deposited at the start of the infection. In the analysis
that follows, the number of bacteria deposited for each animal was
calculated using each individual animals presented dose and the
average deposited dose from Table 1 (i.e., 4.63% of the individual
presented dose).
Second, for clearance from the airways (BAL data), the data are
presented as the percent remaining of the initial BAL dose for each
animal. Percent remaining was used since the number of bacteria
only decreased over time in this tissue compartment. However,
for analysis of bacteria in lung tissue over time, where bacterial
numbers decreased initially and then increased in some animals
(due to germination and growth in situ or reseeding from the cir-
culating bacteria, see below), and data are expressed as the percent
change of deposited tissue dose.
BACTERIAL CLEARANCE FROM THE AIRWAYS
The number of bacteria in the airways over time was deter-
mined by dilution plate analysis of BAL using methods identical
to that described above for the zero hour time point. Trypan
blue negative (i.e., viable) alveolar macrophages in BAL were also
quantified, which helped to enumerate bacteria by providing an
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Table 4 | Total bacteria in the tracheobronchial lymph nodes (TBLN) and blooda.
Time post-exposure TBLN Blood
# of animals CFU # of animals CFU
1 Hour
Sham-vaccinated 4 0.0 ± 0.0 5 0.0 ± 0.0
AVA-vaccinated 4 0.0 ± 0.0 5 0.0 ± 0.0
6 Hour
Sham-vaccinated 5 0.0 ± 0.0 5 0.0 ± 0.0
AVA-vaccinated 5 0.0 ± 0.0 5 0.0 ± 0.0
12 Hour
Sham-vaccinated 5 44 ± 19 (3)b 5 0.0 ± 0.0
AVA-vaccinated 5 0.0 ± 0.0 5 0.0 ± 0.0
24 Hour (experiment #1)
Sham-vaccinated 5 8785 ± 6397 (2) 5 0.53 ± 0.32(×106)(2)
AVA-vaccinated 5 1315 ± 1139 (2) 5 0.0 ± 0.0
24 Hour (experiment #2)
Sham-vaccinated 5 NQc (3) 5 0.33 ± 0.16(×106)(3)
AVA-vaccinated 5 0.0 ± 0.0 5 5600 ± 3542(2)
36 Hour (experiment #1)
Sham-vaccinated 3d NQ (3) 3 0.34 ± 0.11(×106)(3)
AVA-vaccinated 5 95 ± 95 (1) 5 0.0 ± 0.0
36 Hour (experiment #2)
Sham-vaccinated 4 277 ± 155 (×106) (4) 5 18.69 ± 16.42(×106)(4)
AVA-vaccinated 5 0.0 ± 0.0 5 0.0 ± 0.0
aValues are mean ± SEM.
bNumber in parenthesis are the number of animals testing positive (e.g., 3 of 5 sham-vaccinated animals had positive TBLNs at 12h). However, for determining
mean ± SEM, all data were used (zero’s were included in the calculation).
cNQ = not quantified; 3 of 5 lymph nodes were positive but bacteria were not quantified because plates were too numerous to count.
d2 of 5 animals died prior to 36h.
estimate of lavage efficiency and also provided potential informa-
tion on the host immune response such as the spore/macrophage
ratio in the airways over time. As shown in Figure 1, the number
of total bacteria detected in BAL dropped steadily following expo-
sure and by 36 h less than 5% of the initial dose was detected in
BAL. As shown, 36 h following exposure 2.46 ± 0.33% (n = 8)
and 4.28 ± 2.06% (n = 10) of the initial total bacterial dose
remained detectable in BAL from sham-vaccinated and AVA-
vaccinated rabbits, respectively. Thus, there was no significant dif-
ference detected between sham-vaccinated and AVA-vaccinated
rabbits in total CFU. In contrast, the numbers of macrophages
from AVA-vaccinated rabbits remained unchanged through 36 h,
whereas BAL macrophage numbers from sham-vaccinated rab-
bits appeared to significantly decrease at the 24 h time point
(Figure 1B).
ENUMERATION OF BACTERIA (SPORES AND VEGETATIVE CELLS)
IN LUNG TISSUE
Attempts were made to quantify the number of heat-resistant
and heat-sensitive bacteria in homogenized lung tissue over time.
However, given the potential to render spores heat sensitive due
to artifacts introduced during ex vivo tissue processing (discussed
above), the main focus of these data are on the total number of
heat-sensitive CFU at a particular time point relative to the num-
ber of total CFU deposited in the animal. If the total number of
bacteria in the lung at a given time point exceeds the total number
of bacteria deposited during the exposure, then germination and
growth most likely has occurred at some point in the animal. The
number of detectable spores (heat-resistant CFU) in lung tissue
steadily decreased over time in all animals with the most obvi-
ous decrease occurring within the first six hours of the infection
(Figure 2A) and there was no difference in the number of spores
between sham-vaccinated and AVA-vaccinated rabbits at any time
point examined. Since the lungs were not lavaged prior to homog-
enization, these data include heat-resistant spores in the airways
as well as any in lung tissue. These results suggest spores are effi-
ciently removed from the lung tissue/airways and that vaccination
has no observable effect.
With respect to heat-sensitive CFU, there were noticeable dif-
ferences between vaccinated and non-vaccinated rabbits in the
total number of heat-sensitive CFU over time in the lung. As
shown in Figure 2B, there were no detectable changes in heat-
sensitive CFU from 0–36 h following exposure in AVA-vaccinated
rabbits, suggesting there is no outgrowth of vegetative cells or re-
seeding of lung tissue from the small amounts of bacteria detected
in the circulation during the time period (see Table 4). However,
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FIGURE 1 | Total bacteria (A) and macrophages (B) detected in
BAL fluid. Data were collected from sham-vaccinated () and
AVA-vaccinated () rabbits immediately following exposure (1 h) and
at 6, 12, 24, and 36h post-exposure. For (A), data were collected and
pooled for the 1, 6, and 12h time points from two separate experiments,
and three separate experiments were used for the 24 and 36h time
points [n = 8 − 16 sham- or AVA-vaccinated rabbits per time point].
For (B), n = 5 for the 1, 6, and 12h groups and between 8–10 for the 24 and
36h time points. Macrophage numbers at the zero time point are from five
non-treated, age-matched and weight-matched control rabbits. All data are
mean ± SEM. In (B), at 24h, BAL from sham-vaccinated rabbits had
significantly less macrophages: ∗p = 0.004 compared to sham-vaccinated
time zero animals and ∗∗p = 0.005 compared to AVA-vaccinated rabbits
at the 24h time point.
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FIGURE 2 | Percent change in (A) spores and (B) vegetative bacteria in
homogenized lung tissue from sham-vaccinated () and AVA-vaccinated
() rabbits. Data were obtained immediately following exposure (1 h) and at
6, 12, 24, and 36h post-exposure. All data are expressed as a percent change
(increase or decrease) at a given time point relative to the initial lung tissue
dose. All data are mean ± SEM with five animals per group except for 36h
time point where data were pooled from two separate experiments
(n = 8 − 10 animals).
several sham-vaccinated rabbits showed dramatic increases in
heat-sensitive CFU in lung tissue at 24 and 36 h such that the
levels of bacteria in the lungs exceed the number of bacteria
deposited during exposure. As shown in Figure 2B, 24 h following
exposure the number of heat-sensitive CFU detected in the lung
of the rabbits as a group increased by 745% and remained elevated
through 36 h (approximately 370%). Although there was a trend
of increased heat-sensitive CFU in sham-vaccinated rabbits that
was reproducible, there was no statistical significance (p = 0.17,
Student’s t-test) between sham-vaccinated and AVA-vaccinated
rabbits. It is also noted that the increased CFU in sham-vaccinated
animals shown in Figure 2 did not occur in all animals and out-
liers are largely responsible the effects shown in Figure 2B. The
24 h and 36 h data in Figure 2B for sham-vaccinated rabbits rep-
resents 13 rabbits and only six of them showed increases which
ranged from 20% to greater than 3500%. It is noted that using
these data, it is not possible to determine if the increases in these
six animals are due to in situ replication or re-seeding vegetative
bacteria from circulating bacteria that is detected at these time
points (Table 4).
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BACTEREMIA IN THE TRACHEAL BRONCHIAL LYMPH NODES
(TBLN) AND BLOOD
The total number of bacteria in the TBLN and blood were deter-
mined (Table 4). Bacteria first appeared at 12 h in the TBLN
from sham-vaccinated animals where CFU were detected in three
of five animals (44 ± 19 CFU). This number steadily increased
through 36 h at which time lymph nodes from all animals were
positive with nearly seven million CFU counted on average. In
contrast, AVA-vaccinated rabbits had lower numbers of heat-
sensitive CFU in lymph nodes at 24 h (1315 ± 1139 CFU) with
even lower numbers detected at 36 h (31 ± 106 CFU). CFU were
first detected in the blood of both sham-vaccinated and AVA-
vaccinated rabbits at 24 h. By 36 h, all sham-vaccinated rabbits
were bacteremic whereas no AVA-rabbits had detectable bac-
teria in the blood. As discussed above for lung homogenates
[see “Lung Dose (Deposited Dose) Determined Using Lung
Homogenates”], it is possible that some spores germinated ex vivo
due to artifacts introduced during homogenization of the lymph
nodes or handling of the blood samples. Thus, total CFU is the
most reliable interpretation of the data, but it is worth not-
ing that if spores were in the lymph or blood at the time of
sacrifice and handling the respective sample ex vivo rendered
the spores heat sensitive, then this artifact appears to affect
nearly all spores in the sample because we could not detect
heat sensitive CFU in the TBLN with any confidence and, to
our knowledge, there are no published data available showing
spores circulating in the blood 24–36 h following exposure in this
model.
DISCUSSION
The objective of the current work was to characterize and quan-
tify disease progression in the rabbit following inhalation of lethal
doses of Ames spore aerosols. The initial aim was to determine
what fraction of inhaled spores (presented dose) was deposited
in the lung (tissue dose) during the exposure. Thereafter, the
dissemination of bacteria from the lung to the draining lymph
node and eventually to the circulation was quantified. Attempts
were made to distinguish between spores and vegetative bacte-
ria in some tissue compartments but as discussed throughout
this paper, dilution plate data should be interpreted with caution
due to the potential to introduce artifacts arising from ex vivo
sample handling. Finally, side-by-side comparisons were made
between naïve rabbits and rabbits that had been vaccinated with
the human anthrax vaccine, which is known to provide complete
protection in this experimental model. These observations are
discussed below andwe focus on how the data helps to expand our
understanding of disease progression using this biological model,
as well as how these data can support computational inhalational
models for the rabbit and other species.
Analysis of lung homogenates from two separate studies
(22 rabbits in total) suggested between 4.03–4.63% of the inhaled
dose was deposited in the lung. Analysis of BAL fluid suggested
slightly lower deposition (3.07%) but the BAL data were not sig-
nificantly different from homogenized lung data. To our knowl-
edge, this is the first time deposition of B. anthracis spores has
been examined in rabbits. Lower amounts in BAL are most likely
due to the fact that not all deposited spores can be removed from
the lung through lavage. These deposition data are in excellent
agreement with our computational model of spore deposition in
the rabbit (Gutting et al., 2008). Here, rabbit lung morphometry
was coupled with the physical factors known to dictate particle
flow and retention in the airways (such as spore size) to produce
a model that predicted between 4–5% of the inhaled spore dose
would be deposited in the rabbit lung. In spite of the data repro-
ducibility shown in the current work and the correlation between
these deposition data and preliminary computational model pre-
dictions, 4–5% spore deposition is lower than the historical work
that suggested between 15–20% of inhaled B. anthracis spores
are retained in the lungs of laboratory animals (Barnes, 1947;
Harper and Morton, 1953). There are many reasons that could
explain this discrepancy. For example, Harper andMorton (1953)
based their conclusions on radio labeled spores where it is proba-
ble that a large percentage of the radio-labeled 32P recovered in
the lung came from dead spores and/or spore debris. In con-
trast, the percent deposition presented in the current work is
based on number of viable spores recovered from lung tissue
homogenates. In the work of Barnes (1947), the percent deposi-
tion was based on average literature values for respiratory intake
for a given species, whereas our work factored in individual ani-
mal breathing rates as measured real time during the exposures
using plesthymography. It is also worth noting that in both of
those historical studies, the authors did not detail the section
of lung that was examined and it’s possible that work exam-
ined some of the larger conducting airways which could account
for higher deposition numbers. Furthermore, extraction effi-
ciencies, differences in animal species, method of aerosolization,
spore preparations, spore sizes, animal physiology (e.g., breathing
frequency), and other factors could also contribute to the discrep-
ancies between the historical deposition data and that presented
in the current work. On a final note, in deriving the values pre-
sented in the current work we homogenized and plated a portion
of the right middle lobe. These data were then multiplied by a
factor of six to account for all six rabbit lobes. This approach
assumed equal distribution throughout the entire lung and if
other lobes retain a higher number of spores than the right mid-
dle lobe, then our calculations would be lower than the actual.
Understanding spore deposition is critical to developing any com-
putational model of inhalational anthrax (Weir and Haas, 2011);
especially physiologically-based models of infection where cross-
species extrapolation is based on lung tissue dose (see Gutting
et al., 2008 for review).
In addition to quantity, the current work also began to address
the quality of inhaled spores. It is widely known that the physi-
cal forces placed on bacteria when converting them from liquid
cultures to aerosols can be significant. Indeed, it is thought that
B. anthracis was the first bacteria to be aerosolized in laboratory
infection studies because it is a spore former and was therefore
more likely to survive the shearing forces placed on it during the
procedure (Buchner, 1888; Barnes, 1947; Harper and Morton,
1953). More recent work suggests as high as 50% of non-spore-
forming microbes can be killed from the shearing forces placed
on them during aerosolization (Mainelis et al., 2005). In the
current work, heat-shocked Ames spores were aerosolized, col-
lected in AGIs, and then re-examined for heat-resistance using
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dilution plate analysis. The data presented in Table 1 suggested
approximately 3 of 10 spores recovered from the AGI were viable
when spread on TSA plates, but were rendered non-viable fol-
lowing an additional heat treatment at 65◦C. It is reasonable
to suggest that these spores were rendered heat sensitive pri-
marily due to damage from the shearing forces placed on them
during aerosolization, although other factors in the exposure sys-
tem could also be contributing (such as Triton-X or antifoam).
The most troubling aspect of delivering heat-sensitive damaged
spores to the lung is that loss of heat-resistance is a hallmark
of spore germination. Thus, assessing spore germination in BAL
samples or homogenized lung tissue based on heat resistance in
dilution plate assays was not possible. It is also not known how
damaged spores interact with the host compared to undamaged
spores (are they cleared faster, do they germinate at all?), but
others have shown that modifying healthy spores by promoting
or inhibiting germination prior to delivery to the airways can
significantly affect disease outcome (McKevitt et al., 2007; Cote
et al., 2009). We have examined other methods in an attempt
to detect and quantify germination in the lung, such as PCR
and microscopy (data not shown), and these are the subject of
ongoing investigations.
Deposited bacteria were cleared quickly from the airways.
Analysis of BAL samples over time revealed that approximately
80% of the spores were cleared from the conducting airways
within six hours (Figure 1). Thereafter, viable bacterial num-
bers continue to decrease such that at 36 h post-exposure less
than 4% of the deposited dose remains detectable in BAL sam-
ples. It is likely that a large portion of the deposited spores were
cleared via the ciliated epithelium that extends throughout the
respiratory tract down to the small bronchioles. This mechanism
of clearance in mammals is exceptionally efficient (approaching
2 cm/min) and observations made by others using Bacillus subtilis
suggested as much as 70% of the spores retained in the airways
following inhalation are cleared through this mechanism (Harper
and Morton, 1953). Another mechanism of B. anthracis spore
clearance from the airways is through phagocytosis by alveolar
macrophages with subsequent transport across the lung epithe-
lium to the lymph nodes (Young et al., 1946; Barnes, 1947; Guidi-
Rontani, 2002). In the current work, total bacteria appeared in
the TBLN between 6–12 h following exposure in sham-vaccinated
rabbits and between 12–24 h in AVA-vaccinated rabbits (Table 4).
For naïve rabbits, this was well before any bacteria were detected
in the circulation (Table 4). These data support the hypothesis
that motile immune cells such as macrophages or dendritic cells
are transporting a portion of the deposited bacteria from the air-
ways to the lymph nodes, but do not prove that is occurring
and if so, whether or not this is the only mechanism of dissem-
ination. For additional support of the Trojan horse hypothesis,
we also examined bacterial titers in BAL samples before and
after the sample was sonicated and hypothesized that if alveo-
lar macrophages were efficiently engulfing deposited spores then
many macrophages would be carrying multiple spores. When
spread on a TSA plate these engulfed spores would collectively
form a single CFU. However, if the macrophage was destroyed
(via sonication) prior to plating then the engulfed spores would
disseminate in the sample and the CFU would increase. In the
analysis, 77% of the BAL samples had more CFU post-sonication
when directly compared to the same sample prior to sonication
(data not shown). Qualitatively, microscopy of BAL also revealed
spores associated with alveolar macrophages (data not shown). In
summary, these data show deposited spores were quickly cleared
from the airways and suggest a portion of them were associated
with resident alveolar macrophages during this process. Clearance
from the lung is the main parameter in the competing risks
model of inhalational anthrax when examining dose-response
and incubation period (Brookmeyer et al., 2005; Wilkening, 2006,
2008), as well as when modeling post-exposure antibiotic treat-
ment or vaccination (Brookmeyer and Blades, 2002; Brookmeyer
et al., 2003, 2004). However, all of that work is based off of
data collected in a non-human primate model of inhalational
anthrax. Therefore, it would be important to examine these mod-
els in a second species, such as the rabbit, and this ongoing in
our lab.
A central question during disease progression is whether or
not spore germination occurs in the lung tissue during trans-
port from the airways to the lymph nodes and if so, do a portion
of the newly germinated spores escape the immune system and
enter extracellular outgrowth in the lung tissue. Or, in contrast,
do spores germinate and escape only after arriving in the lymph
node. Historical studies that used virulent strains of B. anthracis
suggested the lung was not conducive to germination and that
most, if not all, germination and escape occurred once the spores
arrived in the draining lymph nodes (Henderson et al., 1956;
Brachman et al., 1966; Grinberg et al., 2001). However, more
recent studies using attenuated strains suggested germination
occurred in lung tissue (Lyons et al., 2004; Glomski et al., 2007;
Sanz et al., 2008). Determining when and where germination is
occurring in the rabbit-Ames aerosol model has proved equally
challenging for two main reasons. First, the time point at which
some animals show dramatic increases in lung CFU (higher than
the total number of CFU deposited in the lung) is a time that
is also associated with detection of circulating bacteria (24 h:
Figure 2, Table 4). It is therefore possible that the increases in the
lung are due to re-seeding from the circulation and not outgrowth
during transport from the airways to the lymph nodes. Second, as
discussed previously, inhalation of heat-sensitive damaged spores,
in addition to ex vivo processing that can render spores heat
sensitive, make interpretation of dilution plate data pre- and post-
heat kill near impossible. Although ultimately inconclusive when
defining the state of the spore, these data are still valuable when
viewed as total CFU in the lung over time with respect to charac-
terizing therapeutic windows and modeling the general infection
process.
As disease progressed in sham-vaccinated rabbits, heat-
sensitive CFU were detected in the tracheal bronchial lymph
nodes (TBLNs) 12 h following inhalation and then in the blood
by 24 h (Table 4). Total bacterial numbers continued to increase
in both TBLNs and blood through 36 h at which point in time
2 of 10 sham-vaccinated rabbits had died. These data support
the hypothesis that dissemination following inhalation is from the
lung through the lymph nodes to the circulation. The data agree
with the work of Hughes et al. (1956) who showed using inhaled
M36 strain B. anthracis spores that cannulation and blockage
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of the rabbit lymphatics delayed disease onset but did not pre-
vent it completely. These data are also in good agreement with
Barnes (1947), who used a virulent strain of B. anthracis to show
replicating bacteria in TBLNs 24 h following inhalation and Ross
(1957), who concluded spores ingested by phagocytic cells are
carried to the TBLNs where they proliferated. Finally, these data
also agree with the data published by Kobiler et al. (2006), who
showed bacteremia in the blood of rabbits 18–90 h following
intranasal installation of Vollum spores and Yee et al. (2010) who
showed bacteremia in rabbits following inhalation of Ames spores
23.1 ± 0.2 h. Although the present work cannot rule out passage
of bacteria from the lung or the lymph node directly into the cir-
culation, the data does suggest if bacteria enter the blood via these
more direct routes it is occurring about the same time as passage
from the lymph to the blood.
The main use of AVA in this work was as an experimental
control to aid in the interpretation of data collected from sham-
vaccinated (naïve) rabbits. By pairing sham-vaccinated rabbits
side-by-side with AVA-vaccinated rabbits, we were able to study
host-pathogen interactions in groups of rabbits that demon-
strate vastly different outcomes when presented with the same
inhaled dose of spores. However, the data collected may also
be useful for investigators studying the protective mechanisms
associated with AVA vaccination and in particular, the combi-
nation of vaccination and post-exposure antibiotic treatment.
The predominant effect of vaccination with AVA is production
of anti-protective antigen (PA) antibodies and the level of anti-
PA at the time of spore challenge is correlated with the level of
protection in the rabbit (Fellows et al., 2001; Pitt et al., 2001).
The mechanism of protection likely involves toxin neutraliza-
tion (Brachman and Friedlander, 1999), which when neutralized
from toxin-producing bacteria, would give the host a signifi-
cant advantage in clearing the invading bacteria. The data pre-
sented here suggest vaccinated rabbits had a systemic infection
because heat-sensitive CFU were detected in the lymph node
(24–36 h post-exposure) and circulation (24 h only) following
aerosol exposure to spores. In both the lymph nodes and blood,
the level of vegetative bacteria appeared to peak 24 h following
exposure. These data may aid investigators in defining a ther-
apeutic window based on vegetative bacteria in specific tissue
compartments.
As discussed previously, the main objective of the data col-
lected in the current work is for use in developing computational
models of anthrax to better understand disease, aid in drug devel-
opment, and contribute to developing human risk assessments
(reviewed in Gutting et al., 2008). There are several prelimi-
nary models inhalational anthrax models published to date that
examine systemic disease (Kumar et al., 2008; Day et al., 2011).
Information relating to bacterial numbers in specific tissues, ger-
mination, and kinetics presented in the current work may be
useful in defining parameter values in these types of determin-
istic models. Additionally, the bacterial clearance rate from the
lung of the rabbit as well as other information presented here
has direct application in the competing risks stochastic model of
inhalational anthrax that has been developed for man using non-
human primate data (Brookmeyer et al., 2003, 2005; Wilkening,
2008).
In summary, the current work quantified the deposition and
dissemination of fully virulent Ames spores in naïve and AVA-
vaccinated rabbits following aerosol exposure of lethal doses. The
data suggested there was a systemic infection in both groups as
bacteria were detected 24 h following exposure in the circulation.
In vaccinated rabbits the numbers of bacteria were low and tran-
sient. In contrast, naïve rabbits demonstrated increasing bacterial
numbers over time in the lung tissue, lymph node, and the circu-
lation. These data may be useful in advancing our understanding
of inhalational anthrax, defining therapeutic windows and devel-
oping computational models of disease for use in human risk
assessments.
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